However, the two services agreed that a fourth dose of the vaccine, also known as a second booster, could be given to people over the age of 80, according to SchengenVisaInfo.com. The ECDC and the EMA have noted that there is currently no clear evidence that vaccine protection against severe disease is significantly reduced in adults aged 60 to 79 years who have a normal immune system and therefore suggest that there is no need to take of the fourth dose. Despite this conclusion, it was stressed that the authorities will continue to monitor the data to determine if there is an increased risk of disease in those who have already been vaccinated. “If the current epidemiological situation changes and new signs emerge, it may be necessary to consider a fourth dose in this age group. “In the meantime, national authorities will also look at local data to decide whether to use a fourth dose in people at higher risk,” the EMA said. In adults under 60 with a normal immune system, it has been explained that there is currently no convincing evidence that vaccine protection is reduced or that there is added value to a fourth dose. As for the additional amplifier, so far no safety concerns have arisen. Therefore, re-vaccination campaigns could be launched in the autumn. However, the authorities will be able to choose the best time for additional doses. “The ECDC and the EMA are urging EU citizens to supplement their plans for both initial and booster vaccinations in line with national recommendations. “By the end of March 2022, 83 percent of adults had received full initial vaccinations and only 64 percent had received a booster dose,” the services added. The ECDC and the EMA have once again emphasized that vaccination against COVID-19 remains the most effective way to prevent serious diseases. Thus, it has been proposed that the EU authorities take a final decision on the marketing of vaccines, including booster vaccines, taking into account factors such as the emergence of new variants, the effects of COVID-19 on different populations and the spread of infection. Evidence suggests that a second booster dose given at least four months after the first booster restores antibody levels without raising safety concerns. In addition, the data also suggest that a second amplifier provides additional protection, although the duration of the benefits is still unknown and the data are still limited.
